Company Description
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States.
It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms.
The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019.
Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 25 |
| CEO | John T. Cavan |
Contact Details
Address: 399 Thornall Street, First Floor Edison, New Jersey 08837 United States | |
| Phone | 732-902-4000 |
| Website | hepionpharma.com |
Stock Details
| Ticker Symbol | HEPA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001583771 |
| CUSIP Number | 426897104 |
| ISIN Number | US4268973025 |
| Employer ID | 46-2783806 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| John T. Cavan | Interim Chief Executive Officer and Chief Financial Officer |
| Sharen Pyatetskaya | Director of Investor Relations |
| Dr. John Z. Sullivan-Bolyai | Part-Time Consultant |
| Dr. Stephen A. Harrison FACP, M.D. | Scientific Advisory Board Chair and Consultant Medical Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 16, 2024 | 10-K | Annual Report |
| Apr 1, 2024 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Mar 6, 2024 | 8-K | Current Report |
| Feb 20, 2024 | 8-K | Current Report |
| Feb 16, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 7, 2024 | 8-K | Current Report |
| Jan 3, 2024 | 8-K | Current Report |
| Dec 7, 2023 | 8-K | Current Report |
| Nov 20, 2023 | 10-Q | Quarterly Report |